How Halozyme Will Continue to Grow With Its New Deal
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 263The 4 Overlooked Winners of ASCO
ThinkstockThe American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across the health care sector flock to this conference to share results from their most…
Can Celladon Turn Itself Around With Its New Plan?
Celladon has announced that its board of directors unanimously approved a strategic plan to pursue either an acquisition or a partnership.
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St. has taken a look at a few of the major ASCO winners so far. Color and background information has also been added on each, as well as how shares have been…
3 Specialty Pharma Stocks That Could Be Acquired in 2015
If there ever was a perfect storm for large pharmaceutical and big-cap biotech companies to make acquisitions to enhance growth it is now.
Short Sellers More Selective on Big Pharma Stocks
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
Short Sellers Get Even More Ambitious Against Biotech Leaders
The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks.
Protests Against Monsanto in 400 Cities
Genetically modified organisms (GMO) are bad for people, the environment, and water supplies, at least. This is according to the protestors involved in the “March Against Monsanto.” Their protests cover 421 cities, 48 countries,…
The Most Loved Biotechs of Big Hedge Funds
There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend Monitor.
Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair share of attention so far…
Why Baxter May Be Very Undervalued Into Breakup
If Merrill Lynch's Bob Hopkins and team are correct, Baxter International is worth a lot more than its current share price would indicate.
How to Evaluate a 50% Move in AVEO
When investors see stocks run up 50% or more on a news release, they probably just assume the company is being acquired.
Has MannKind Stock Finally Bottomed Out?
After looking at the recent recovery, and after looking over the more recent news that has come out after earnings, 24/7 Wall St. wants to see if MannKind shares have finally reached their bottom.
How Sarepta Short Interest Is Adding to Its Gains
Analysts are beginning to flock to Sarepta after the company made news surrounding a meeting with the FDA, not to mention the enormous boost that shares are getting from short covering.
Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years?
Johnson & Johnson has been working on its pharmaceuticals pipeline for a while, and plans on continuing to do so.